适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Abivax
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study to investigate the effects of multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone) in healthy female participants of childbearing potential.Healthy female participants of childbearing potential.MedDRA version: 21.1Level: LLTClassification code: 10003268Term: Arthritis rheumatoid Class: 10028395MedDRA version: 20.1Level: PTClassification code: 10021972Term: Inflammatory bowel disease Class: 100000004856CTIS2023-505297-15-00Abivax36
招募中
1 期
A Phase 1, 2-part, open-label, single-sequence study to investigate the effect of single and multiple doses of obefazimod on the pharmacokinetics of rosuvastatin in healthy male participants.Moderately to severely active ulcerative colitisMedDRA version: 20.0Level: PTClassification code: 10009900Term: Colitis ulcerative Class: 100000004856CTIS2023-509226-21-00Abivax24
进行中（未招募）
1 期
A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.Moderately to severely active ulcerative colitisCTIS2024-514561-20-00Abivax48
进行中（未招募）
1 期
A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by the body and to assess the extent to which SAR441566 becomes available to the body when given by mouthCTIS2023-508030-33-00Sanofi-Aventis Recherche & Developpement13
招募中
1 期
Investigation of safety, tolerability and pharmacokinetics of multiple doses of NNC0113-6856 in healthy participants, including a subset of healthy Japanese participantsType 2 diabetesMedDRA version: 21.1Level: LLTClassification code: 10045242Term: Type II diabetes mellitus Class: 10027433CTIS2023-503891-26-00ovo Nordisk A/S170